Tech Company Financing Transactions
Avenge Bio Funding Round
Avenge Bio, operating out of Natick, secured $45 million from CAM Capital, Perceptive Advisors and Longitude Capital Management.
Transaction Overview
Company Name
Announced On
1/11/2022
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
CAM Capital (Lead Investor)
Perceptive Advisors (Lead Investor)
Proceeds Purpose
The company intends to use the funds: to advance its lead program, AVB-001, through the filing of an Investigational New Drug (IND) application and into the clinic for the treatment of metastatic peritoneal cancers, with a primary focus on recurrent and refractory ovarian cancer, and to continue the rapid development of its pipeline programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
22 Strathmore Rd. 241
Natick, MA 01760
USA
Natick, MA 01760
USA
Phone
Website
Email Address
Overview
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyte platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Heffernan
Founder
Omid Veiseh
Founder
Paul Wotton
VP - Operations
Ryan Newman
Browse more venture capital transactions:
Prev: 1/11/2022: Maze Therapeutics venture capital transaction
Next: 1/11/2022: Arive GmbH venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs